A Phase 3 interventional study of Esophagectomy in Esophageal Carcinoma and Esophageal Cancer, sponsored by UMC Utrecht. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-26.
Sponsored by UMC Utrecht · Phase 3, Interventional, and Treatment
This is the first randomized controlled trial designed to compare robot-assisted minimally invasive thoraco-laparoscopic esophagectomy with open transthoracic esophagectomy as surgical treatment for resectable esophageal cancer.
If our hypothesis is proved correct, robot-assisted minimally invasive thoraco-laparoscopic esophagectomy will result in a lower percentage of postoperative complications, lower blood loss, shorter hospital stay, but with at least similar oncologic outcomes and better postoperative quality of life compared with the open transthoracic esophagectomy (current standard).
Rationale: As stated in the 2010 revised Dutch esophageal carcinoma guidelines, the golden standard for surgical treatment of esophageal carcinoma is open transthoracic esophagectomy. Recent evidence suggests that robot-assisted thoraco-laparoscopic esophagectomy using the Da Vinci ® robot can provide an extensive resection, with possibly better or at least equal radical (R0) resection rates and an equal number of dissected lymph nodes. This is accompanied with markedly reduced blood loss and reduction of overall complications with shorter intensive care unit (ICU) and hospital stay. Therefore, the robot-assisted thoraco-laparoscopic esophagectomy is now at a stage that it should be compared to the current standard of care in a randomized controlled trial.
Objective: Evaluate the benefits, risks and costs of robot-assisted thoraco-laparoscopic esophagectomy as an alternative to open transthoracic esophagectomy as treatment for esophageal cancer.
Study design: Randomized controlled parallel-group superiority trial Study population: Patients (age ≥ 18 and ≤ 75 jaar) with histologically proven surgically resectable (cT1-4a, N0-3, M0) squamous cell carcinoma, adenocarcinoma or undifferentiated esophageal carcinoma of the intrathoracic esophagus with European Clinical Oncology Group (ECOG) status 0, 1 or 2.
Intervention: 112 patients will be randomly allocated to either A) robot-assisted thoraco-laparoscopic esophagectomy (n=56) or B) open transthoracic esophagectomy (n=56).
Patients will receive the following interventions:
Group A. Robot-assisted thoraco-laparoscopic esophagectomy, with gastric conduit formation.
Group B. Open transthoracic esophagectomy, with gastric conduit formation.
Main study parameters/endpoints: Primary outcome is the percentage of overall complications (Grade 2 and higher) as stated by the modified Clavien-Dindo classification (MCDC).
Secondary outcomes are individual components of the primary endpoint (major and minor complications), (in hospital) mortality within 30 and 60 days, R0 resections, operation related events, postoperative recovery, oncologic outcomes, cost-effectiveness and quality of life.
Follow-up: 60 months after randomization
1,631 studies on the registry are indexed under Esophageal Neoplasms; 469 are open to participants now.
This study's enrollment of 112 is above the median of 60 across 1,198 interventional studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →UMC Utrecht is the lead sponsor of 363 studies on the registry; 81 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
Procedure: Esophagectomy
traditional open transthoracic esophagectomy with gastric conduit formation.
Procedure: Esophagectomy
In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
Also known as: robot-assisted minimally invasive esophagectomy, robot-assisted thoraco-laparoscopic esophagectomy
Postoperative complications modified Clavien-Dindo classification (MCDC) grade 2 and higher
The primary outcome of this study is the percentage of overall complications (Grade 2 and higher) as stated by the modified Clavien-Dindo classification of surgical complications (MCDC)
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Individual components of the primary endpoint (major and minor complications)
Major complications (MCDC grade 2-4) Including: myocardial infarction, anastomotic leakage (clinical or radiologic diagnosis), anastomotic stenosis, chylothorax (chylous leakage, presence of chylous in chest tubes or indication start medium chain triglycerides containing tube feeding (Vivonex®), gastric tube necrosis (proven by gastroscopy), pulmonary embolus, deep vein thrombosis, vocal cord palsy or paralysis. Minor complications (MCDC grade 1) Including: wound infections, pleural effusions, delayed gastric emptying
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
(In hospital) Mortality within 30 and 60 days
(In hospital) mortality and mortality within 30 and 60 days will be reported. The cause of death and the results of the autopsy report will be noted.
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks and within 30 days or 60 days
R0 resections (%)
The pathological analysis will be finished within 2 weeks.
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Operation related events
Operation time is defined as time from incision until closure (minutes) for both the thoracic and the abdominal phase of the procedure. For the robotic procedure, set up time will be recorded separately. Unexpected events and complications occurring during the operation will be recorded (e.g. massive hemorrhage, perforation of other organs). Blood loss during operation (ml, per phase). In case of conversion to thoracotomy or laparotomy the reason for conversion has to be explained (absolute numbers/percentage).
Time frame: Day of surgery, up to 24 hours after surgery.
Postoperative recovery
Pain: Type and dose of used analgesics will be noted during the hospital admission period. Visual Analogue Scale (VAS) for pain will be noted at following times: pre-operatively and the first 10 days after surgery and a fixed periods during follow up (6 weeks, 6 months and yearly post-operatively up to 5 years). Length of intensive care unit (ICU) - medium care unit (MCU) stay (days). Length of hospital stay (days).
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Oncologic outcomes
2, 3 and 5 year disease free and overall survival
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months after surgery.
Quality of life
Questionnaires will be required at following times: SF-36, EORTC QLQ-C30 (Dutch), EORTC OES18 (Dutch) and EQ-5D (Appendix 1 \& 2) pre-operative \< 5 days and 6 weeks, 6 months and yearly up to 5 years post-operatively.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months after surgery.
Costs (euro)
Direct general costs, due to extra operating room time and extra instruments. Indirect costs, such as reduced ICU or hospital stay.
Time frame: 5 years follow up
Plan to share: Undecided
Ran from Apr 2012 to primary completion in Aug 2016, 52 months.
Of 56 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 106. This study's 52 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.